Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262856 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT04262856 is a Phase 2 study that has completed, run by Arcus Biosciences. The registered enrollment target is 151 participants.
The verdict
NCT04262856, a Phase 2 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.
Interventions
- DRUG Zimberelimab
- DRUG Domvanalimab
- DRUG Etrumadenant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04262856
The ClinicalTrials.gov registry entry for NCT04262856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zimberelimab is the first listed.
NCT04262856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04262856 about?
NCT04262856 is a clinical study titled "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer". This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small ce...
What is the current status of trial NCT04262856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2020-05-28. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT04262856?
The interventions under investigation include: Zimberelimab (DRUG), Domvanalimab (DRUG), Etrumadenant (DRUG).
Who is sponsoring clinical trial NCT04262856?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.